Regenxbio Inc at World Muscle Society 2023 Data Update Transcript
Thank you for standing by, and welcome to REGENXBIO RGX-202 Interim Data Call. (Operator Instructions) I would now like to hand the call over to President and CEO, Ken Mills. Please go ahead.
Hello. Good afternoon, everyone. This is Ken. If you're joining through the webcast, there are slides available, and they are self-guided. If you're joining on the phone, the slides are available on the Investors section of our website.
I'm going to start on Slide 2. Thanks for joining the call today. I'm very excited, so we'll get right into it. We have 2 updates today. First, we're reporting an update on patients dosed with RGX-202 from dose level 1 of our AFFINITY DUCHENNE study. This update will be presented at the World Muscle Society Conference in Charleston, South Carolina this week. Compared to our last update in July, this will include additional patient longer-term follow-up safety and first measures of RGX-202 microdystrophin expression from patient biopsies that are collected at 3 months.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |